Evidence map›Paper›PMID 37376376›Full record

ReviewPolymers2023

Development of Stereocomplex Polylactide Nanocomposites as an Advanced Class of Biomaterials-A Review.

Muhammad Samsuri, Purba Purnama

Abstract readReview
In one paragraph

Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Muhammad SamsuriChemical Engineering Department, Universitas Bhayangkara Jakarta Raya, Bekasi 17121, West Java, Indonesia.
Purba PurnamaSchool of Applied STEM, Universitas Prasetiya Mulya, Tangerang 15339, Banten, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review paper analyzes the development of advanced class polylactide (PLA) materials through a combination of stereocomplexation and nanocomposites approaches. The similarities in these approaches provide the opportunity to generate an advanced stereocomplex PLA nanocomposite (stereo-nano PLA) material with various beneficial properties. As a potential "green" polymer with tunable characteristics (e.g., modifiable molecular structure and organic-inorganic miscibility), stereo-nano PLA could be used for various advanced applications. The molecular structure modification of PLA homopolymers and nanoparticles in stereo-nano PLA materials enables us to encounter stereocomplexation and nanocomposites constraints. The hydrogen bonding of D- and L-lactide fragments aids in the formation of stereococomplex crystallites, while the hetero-nucleation capabilities of nanofillers result in a synergism that improves the physical, thermal, and mechanical properties of materials, including stereocomplex memory (melt stability) and nanoparticle dispersion. The special properties of selected nanoparticles also allow the production of stereo-nano PLA materials with distinctive characteristics, such as electrical conductivity, anti-inflammatory, and anti-bacterial properties. The D- and L-lactide chains in PLA copolymers provide self-assembly capabilities to form stable nanocarrier micelles for encapsulating nanoparticles. This development of advanced stereo-nano PLA with biodegradability, biocompatibility, and tunability properties shows potential for use in wider and advanced applications as a high-performance material, in engineering field, electronic, medical device, biomedical, diagnosis, and therapeutic applications.

Indexed as

advanced materialsbiodegradable polymersinterfacial interactionnanoparticlesnucleating agentpolylactideself-assemblystereocomplexthermal and mechanical properties

Identifiers

PMID37376376
PMCPMC10305411

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.